TAK-058 Placebo

DRUG2 trials

Sponsors

Takeda

Conditions

Healthy VolunteersSchizophrenia

Phase 1

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

CompletedNCT02389881

TakedaHealthy Volunteers

Start: 2015-02-28End: 2015-12-31Updated: 2017-02-23

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

TerminatedNCT02614586

TakedaSchizophrenia

Start: 2015-12-31End: 2016-04-30Updated: 2017-05-01